Trial Profile
A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Estradiol/norethisterone
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 01 May 2022 Results published in the Clinical Pharmacology in Drug Development
- 30 Aug 2019 Status changed from active, no longer recruiting to completed.
- 05 Aug 2019 Planned End Date changed from 3 Jul 2019 to 19 Aug 2019.